Speaker: Barbara Burtness

0:00:47

Novel KRAS-targeting agents on the horizon

1:30:01

Defining Mechanisms and Biomarkers of Sensitivity & Resistance To Anti-Cancer Treatments

0:00:58

Checkpoint inhibitors for head and neck cancer in the definitive setting?

0:10:08

Evolving role of HER2 targeted therapies in gastroesophageal cancers

0:04:11

CDKN2A and TP53 mutation in HPV-negative HNSCC

0:52:24

Debbie's Dream Foundation Curing Stomach Cancer - Clinical Trials for the Cancer Patient Webinar

0:03:08

KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC

0:00:35

Data on KRAS inhibitors in lung cancer at WCLC 2022

0:04:00

Reduced postoperative therapy in patients with OPC: ECOG-ACRIN 3311

0:03:50

Pharma speaking programs in cancer immunotherapy Keytruda, Opdivo, Tecentriq in California & Arizona

0:07:03

Pembrolizumab for frontline head and neck cancer: KEYNOTE-048 results

0:07:56

KEYNOTE-048: progression post next line for R/M HNSCC

0:02:52

Dr Barbara McAneny: Success in OCM Seems Like a “Random Event”

0:22:39

THỰC HÀNH LÂM SÀNG PHỐI HỢP HÓA XẠ TRỊ TRONG ĐIỀU TRỊ UNG THƯ TẾ BÀO GAI VÙNG ĐẦU CỔ

2:03:36

Pós ASCO Virtual GBCP 2020